Denali Therapeutics Inc.
Live Market Data
About Company
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Industry Segment
Price Chart
Technical Analysis
Technical Outlook
Valuation Check
Research Reports
Daily – Vickers Top Buyers & Sellers for 01/12/2026
Daily – Vickers Top Buyers & Sellers for 01/09/2026
Quarterly Results
| Particulars | Dec 25 | Sept 25 | Jun 25 | Mar 25 | Dec 24 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 0 | 0 | 0 |
| Net Income (Cr) | -12.85 | -12.69 | -12.41 | -13.3 | -11.48 |
| EPS (₹) | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 |
Annual Profit & Loss
| Particulars | 2025 | 2024 | 2023 | 2022 | 1970 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 33.05 | 10.85 | 0 |
| Operating Exp (Cr) | 55.53 | 50.19 | 52.72 | 44.92 | 0 |
| Net Income (Cr) | -51.25 | -42.28 | -14.52 | -32.6 | 0 |
| EPS (₹) | 0 | -2.57 | -1.06 | -2.6 | -2.39 |
Balance Sheet
| Particulars | Dec 25 | Sept 25 | Jun 25 | Mar 25 | Dec 24 |
|---|---|---|---|---|---|
| Total Assets (Cr) | 114.49 | 105.56 | 116.62 | 127.13 | 137.42 |
| Total Liabilities (Cr) | 13.11 | 12.94 | 13.92 | 14.87 | 14.45 |
| Total Equity (Cr) | 101.38 | 92.62 | 102.71 | 112.27 | 122.97 |
Key Ratios Fundamentals
Valuation
Profitability
Liquidity & Debt
Price Statistics
Pattern Unavailable
Detailed shareholding breakdown is not currently provided by the exchange.